5 citations,
March 2021 in “Journal of The American Academy of Dermatology” Low-dose oral minoxidil is an effective and safe treatment for hair loss.
5 citations,
September 2017 in “Plastic and Aesthetic Research” Low dose cyclical nutrition therapy can consistently and safely improve hair growth and density without needing anti-androgens.
4 citations,
February 2022 in “JAAD case reports” The document concludes that low-dose oral minoxidil successfully regrew hair in a patient with permanent hair loss after chemotherapy and stem cell transplant.
4 citations,
October 2021 in “Journal of The European Academy of Dermatology and Venereology” 4 citations,
January 2019 in “PubMed” Low dose valproate in epileptic children mainly causes weight gain and other non-life-threatening side effects.
4 citations,
January 2019 in “Dermatology Online Journal” Low-dose naltrexone might be a cheap and effective additional treatment for hair loss with scalp discomfort due to its anti-inflammatory effects and few side effects.
3 citations,
August 2022 in “Journal of The American Academy of Dermatology” A 24-week randomized double-blind clinical trial evaluated the efficacy and safety of low-dose oral minoxidil (LDOM) at 0.25 mg/day versus 1 mg/day for treating female pattern hair loss (FPHL) in 30 women. The study found that the 1 mg/day dose significantly increased hair count (P < .001) compared to the 0.25 mg/day dose, which did not show significant improvement (P = .20). Both doses improved hair-shedding scores and quality of life, but no significant differences were observed between the groups in these measures. Mild facial hypertrichosis was noted in two patients on the 1 mg/day dose. The study concluded that LDOM 1 mg/day is effective and well-tolerated for FPHL, with superior efficacy to the 0.25 mg/day dose. Limitations included the small sample size and lack of a placebo group.
3 citations,
September 2019 in “Journal of The American Academy of Dermatology” Low-dose oral minoxidil effectively treats mild-moderate male hair loss, alone or combined with other therapies.
3 citations,
May 2016 in “Gynecological Endocrinology” Low-dose flutamide improved hirsutism and satisfaction in women but had common side effects, causing some to stop treatment.
3 citations,
May 2014 in “Dermatologic Surgery” Low-dose finasteride may cause muscle weakness and eye issues, but stopping the drug can lead to recovery.
2 citations,
January 2023 in “Curēus” Low-dose naltrexone may help reduce redness in certain scalp conditions.
2 citations,
July 2022 in “Journal of the American Academy of Dermatology” The safety and tolerability of low-dose oral minoxidil for treating hair loss in adolescents is not clearly determined.
2 citations,
May 2021 in “Journal of The American Academy of Dermatology” Low-dose oral minoxidil for hair loss seems to have rare side effects, but more research is needed to confirm its safety.
2 citations,
January 2010 in “Hormone Molecular Biology and Clinical Investigation” Low dose finasteride decreases certain steroids, possibly increasing depression risk.
1 citations,
September 2023 in “Dermatology online journal” Low dose oral minoxidil can help with hair growth but may cause serious heart problems, so doctors need to be careful.
1 citations,
September 2023 in “Journal of The American Academy of Dermatology” Low dose oral minoxidil can help with hair loss when used alone.
1 citations,
June 2023 in “Radiation oncology journal” Low-dose radiation therapy may improve brain function in some Alzheimer's patients and is generally well-tolerated.
1 citations,
May 2022 in “Journal of Drugs in Dermatology” Low-dose naltrexone and platelet-rich plasma can regrow hair in lichen planopilaris.
1 citations,
August 2021 in “Cosmoderma” The review concluded that low-dose oral minoxidil (OM) was an effective and well-tolerated treatment for various types of hair loss, including androgenetic alopecia and other forms of alopecia. Dosages ranged from 0.25 mg to 10 mg, with lower doses (<2.5 mg) being more common to minimize side effects. Studies involving up to 435 patients reported significant hair regrowth and high patient satisfaction, with side effects generally being mild and reversible. Despite not being FDA-approved for this use, OM was found to be more convenient, cost-effective, and better tolerated than topical minoxidil, making it a viable alternative for hair loss treatment.
1 citations,
August 2019 in “Environmental Toxicology” Exposure to low doses of finasteride in the womb causes changes in the prostate of both male and female gerbils.
1 citations,
July 2017 in “The Journal of Urology” Low-dose finasteride and dutasteride reduce PSA levels by 27.8% in men with male androgenetic alopecia.
September 2024 in “JAMA Dermatology” Low-dose metformin may help hair regrowth and reduce inflammation in CCCA.
September 2024 in “Journal of the American Academy of Dermatology” Low-dose oral minoxidil helps hair regrowth in COVID-19-related hair loss with few side effects.
September 2024 in “Journal of the American Academy of Dermatology” Experts agree on guidelines for safely using low-dose oral minoxidil to treat hair loss.
August 2024 in “Archives of Dermatological Research” Low-dose oral minoxidil is effective and safe for treating androgenetic alopecia.
August 2024 in “Skin Research and Technology” July 2024 in “Skin Appendage Disorders” Low dose oral minoxidil is safe for treating hair loss in men.
July 2024 in “Journal of the American Academy of Dermatology” Low-dose oral minoxidil is generally safe for hypertensive patients with hair loss.
June 2024 in “British Journal of Dermatology” PRP with topical minoxidil is the most effective treatment for increasing hair density in androgenetic alopecia.
June 2024 in “British Journal of Dermatology” Combining PRP with topical minoxidil is the most effective for increasing hair density in male pattern baldness.